menu
    • menu

    Company profile for Eris Lifesciences

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Eris Lifesciences Ltd is a leading Indian pharmaceutical company, ranked #21 in the IPM, specializing in chronic and sub-chronic therapies (~87% of revenue). Established in 2007, it dominates the cardio-metabolic segment while expanding into dermatology, neuropsychiatry, and gynecology (26% of revenue). With a strong presence in India’s ₹55,000+ crore chronic care market, Eris focuses on specialist-driven, innovative treat...
    Eris Lifesciences Ltd is a leading Indian pharmaceutical company, ranked #21 in the IPM, specializing in chronic and sub-chronic therapies (~87% of revenue). Established in 2007, it dominates the cardio-metabolic segment while expanding into dermatology, neuropsychiatry, and gynecology (26% of revenue). With a strong presence in India’s ₹55,000+ crore chronic care market, Eris focuses on specialist-driven, innovative treatments to improve patient outcomes. The company combines cutting-edge medical knowledge with a robust branded formulations portfolio, serving high-end physicians and delivering consistent growth.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Eris Lifesciencesindia-flag Flag
    Country
    Country
    India
    Address
    Address
    Shivarth Ambit, Plot No 142/2, Ramdas Road Off SBR, Near Swati Bungalows, Boda...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://eris.co.in/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eris-lifesciences/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eris Launches Weekly Semaglutide Shot At ?220/Shot
    Eris Launches Weekly Semaglutide Shot At ?220/Shot

    20 Mar 2026

    // EXPRESSPHARMA

    https://www.expresspharma.in/eris-launches-weekly-shot-of-semaglutide-starting-at-rs-220-per-shot/

    EXPRESSPHARMA
    20 Mar 2026
    Share Share
    Eris, Natco Pharma Partner For Semaglutide Launch In India
    Eris, Natco Pharma Partner For Semaglutide Launch In India

    25 Feb 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/eris-lifesciences-partnership-with-natco-pharma-for-semaglutide-launch-in-india-19198

    INDPHARMAPOST
    25 Feb 2026
    Share Share
    CDSCO OKs Most New r-DNA Drugs for 2025 Import & Manufacture
    CDSCO OKs Most New r-DNA Drugs for 2025 Import & Manufacture

    21 Jan 2026

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=183674&sid=1

    PHARMABIZ
    21 Jan 2026
    Share Share
    Delhi HC Restores Ban On 2 Diabetes FDCs
    Delhi HC Restores Ban On 2 Diabetes FDCs

    14 Jan 2026

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/delhi-hc-restores-ban-on-2-diabetes-fdcs/articleshow/126532810.cms

    ECONOMICTIMES
    14 Jan 2026
    Share Share
    Eris Lifesciences Consolidates Its Stake In Swiss Parenterals
    Eris Lifesciences Consolidates Its Stake In Swiss Parenterals

    25 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/eris-lifesciences-consolidates-its-stake-in-swiss-parenterals-18354

    INDPHARMAPOST
    25 Nov 2025
    Share Share
    Indian Pharma Prepares For ?600-800 Cr Insulin Pen Market
    Indian Pharma Prepares For ?600-800 Cr Insulin Pen Market

    22 Sep 2025

    // BUSINESS STD

    https://www.business-standard.com/industry/news/indian-drugmakers-eye-rs800cr-opportunity-as-novo-exits-insulin-pens-125092200599_1.html

    BUSINESS STD
    22 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search